BMRN
9:05 AM
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
Presentation / Abstractbiomarin.com
Catalyst Calendar
Tue, Jun 16, 2026
1 updatesWed, May 20, 2026
1 updatesBMRN
4:20 PM
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
Trial Results • Phase 3biomarin.com
Mon, May 18, 2026
1 updatesMon, May 4, 2026
1 updatesBMRN
4:05 PM
Sat, May 2, 2026
1 updatesMon, Apr 27, 2026
2 updatesTue, Apr 21, 2026
1 updatesBMRN
4:23 PM
BioMarin Announces Board Leadership Transition
biomarin.com